AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18334815 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucan-enriched ready meal (4 g of oat beta-glucans)
Number of subjects: 43
Study 18334815 — intervention group
Group type: COMPARATOR
Intervention: Control soup (without oat beta-glucans)
Number of subjects: 43
Study 18334815 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucan-enriched ready meal
Number of subjects: 43
Study 18334815 — intervention group
Group type: COMPARATOR
Intervention: Control soup
Number of subjects: 43
Study 17136462 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Skills Training prevention program
Number of subjects: 4858
Study 17136462 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4858
Study 12966366 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aceclofenac
Number of subjects: 0
Study 12966366 — intervention group
Group type: COMPARATOR
Intervention: 75 mg diclofenac
Number of subjects: 0
Study 11089711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Heart Disease Shared Decision‐Making Program (IHD SDP)
Number of subjects: 240
Study 11089711 — intervention group
Group type: COMPARATOR
Intervention: Control (usual practice)
Number of subjects: 240
Study 9322828 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80/160 mg
Number of subjects: 734
Study 9322828 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80/80 mg twice daily
Number of subjects: 734
Study 9322828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10/20 mg
Number of subjects: 734
Study 9322828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734
Study 9322828 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan and Lisinopril
Number of subjects: 734
Study 9322828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 734
Study 9322828 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 734
Study 7690462 — intervention group
Group type: EXPERIMENTAL
Intervention: L-697,661 (25 mg twice a day)
Number of subjects: 135
Study 7690462 — intervention group
Group type: EXPERIMENTAL
Intervention: L-697,661 (100 mg three times a day)
Number of subjects: 135
Study 7690462 — intervention group
Group type: EXPERIMENTAL
Intervention: L-697,661 (500 mg twice a day)
Number of subjects: 135
Study 7690462 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (100 mg five times a day)
Number of subjects: 135
Study 7690462 — intervention group
Group type: EXPERIMENTAL
Intervention: L-697,661 (all doses)
Number of subjects: 135
Study 7690462 — intervention group
Group type: EXPERIMENTAL
Intervention: L-697,661 (higher doses)
Number of subjects: 135
Study 30507281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (INT)
Number of subjects: 58
Study 30507281 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 58
Study 29958570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (200 mg via two infusions)
Number of subjects: 56
Study 29958570 — intervention group
Group type: COMPARATOR
Intervention: Oral iron polymaltose complex (100 mg orally twice a day for 8 weeks)
Number of subjects: 56
Study 26763349 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide starting dose of 5 mg/d
Number of subjects: 103
Study 26763349 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide starting dose of 10 mg/d
Number of subjects: 103
Study 26763349 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide starting dose of 15 mg/d
Number of subjects: 103
Study 26763349 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated treatment (to 15 or 20 mg/d)
Number of subjects: 103
Study 26763349 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (any starting dose)
Number of subjects: 103
Study 24531938 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular infiltration analgesia (PIA) with 60 ml 0.5 % ropivacaine and 0.3 mg epinephrine
Number of subjects: 49
Study 24531938 — intervention group
Group type: COMPARATOR
Intervention: Sciatic nerve block (SNB) with 20 ml 0.375 % ropivacaine and periarticular infiltration with 20 ml normal saline and 0.3 mg epinephrine
Number of subjects: 49
Study 24531938 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular infiltration (PIA)
Number of subjects: 49
Study 24531938 — intervention group
Group type: COMPARATOR
Intervention: Sciatic nerve block (SNB)
Number of subjects: 49
Study 22218122 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (500 mg, 2 tablets per day for 5 days before transplantation)
Number of subjects: 99
Study 22218122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 21535171 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band ultraviolet B (NBUVB) + isotretinoin (0.5 mg/kg/day)
Number of subjects: 39
Study 21535171 — intervention group
Group type: COMPARATOR
Intervention: Narrow band ultraviolet B (NBUVB) + placebo
Number of subjects: 39
Study 17047667 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) 50 mg
Number of subjects: 0
Study 16236845 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 5 days
Number of subjects: 552
Study 16236845 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice daily for 10 days
Number of subjects: 552
Study 12198699 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 121
Study 12198699 — intervention group
Group type: COMPARATOR
Intervention: Nadolol plus isosorbide mononitrate (N+I)
Number of subjects: 121
Study 10607989 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude dust extract (CDE)
Number of subjects: 48
Study 10607989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8657436 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐methasone intrathecally prior to wound closure
Number of subjects: 26
Study 8657436 — intervention group
Group type: COMPARATOR
Intervention: normal saline (placebo)
Number of subjects: 26
Study 2089089 — intervention group
Group type: EXPERIMENTAL
Intervention: moclobemide
Number of subjects: 53
Study 2089089 — intervention group
Group type: EXPERIMENTAL
Intervention: brofaromine
Number of subjects: 53
Study 2089089 — intervention group
Group type: COMPARATOR
Intervention: maprotiline
Number of subjects: 53
Study 24645 — intervention group
Group type: EXPERIMENTAL
Intervention: Halazepam (40 mg starting dose, adjusted every 2 hours, total daily dose not exceeding 600 mg)
Number of subjects: 22
Study 24645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31821349 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology taping (KT)
Number of subjects: 54
Study 31821349 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 'rigid' taping (ST)
Number of subjects: 54
Study 31821349 — intervention group
Group type: COMPARATOR
Intervention: Sham taping (ShT)
Number of subjects: 54
Study 28456947 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine discussion of sexual orientation and HPV vaccination
Number of subjects: 220
Study 28456947 — intervention group
Group type: COMPARATOR
Intervention: Not discussing sexual orientation and HPV vaccination
Number of subjects: 220
Study 26951777 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour at 41 GW (early induction)
Number of subjects: 10038
Study 26951777 — intervention group
Group type: COMPARATOR
Intervention: Expectant management and induction at 42 GW (late induction)
Number of subjects: 10038
Study 24528686 — intervention group
Group type: EXPERIMENTAL
Intervention: Armolipid Plus (nutraceutical combination containing red yeast rice extract, berberine, policosanol, astaxanthin, coenzyme Q10, and folic acid)
Number of subjects: 30
Study 24528686 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 10 mg/d
Number of subjects: 30
Study 22492764 — intervention group
Group type: EXPERIMENTAL
Intervention: RC with Lactobacillus reuteri DSM17938 (reuteri)
Number of subjects: 494
Study 22492764 — intervention group
Group type: COMPARATOR
Intervention: RC (regular calcium content)
Number of subjects: 494
Study 22492764 — intervention group
Group type: EXPERIMENTAL
Intervention: RC with Lactobacillus casei CRL431 (casei)
Number of subjects: 494
Study 22492764 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-lactose milk with low calcium content (LC)
Number of subjects: 494
Study 20932058 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise session with 10 seconds rest interval
Number of subjects: 12
Study 20932058 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise session with 1 minute rest interval
Number of subjects: 12
Study 20932058 — intervention group
Group type: COMPARATOR
Intervention: Pre-exercise samples
Number of subjects: 12
Study 20932058 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise samples
Number of subjects: 12
Study 17621463 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV)
Number of subjects: 86
Study 15304466 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg per hour for the duration of PCI) with provisional Gp IIb/IIIa inhibition
Number of subjects: 6010
Study 15304466 — intervention group
Group type: COMPARATOR
Intervention: Heparin (65 U/kg bolus) with planned Gp IIb/IIIa inhibition
Number of subjects: 6010
Study 19785243 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal voluntary contraction (SVC) exercise
Number of subjects: 32
Study 19785243 — intervention group
Group type: COMPARATOR
Intervention: Near-maximal voluntary contraction (NMVC) exercise
Number of subjects: 32
Study 9638490 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tele- and brachytherapy (44 +/- 3 Gy external beam radiation followed by 20 +/- 4 Gy interstitial brachytherapy with iridium-192)
Number of subjects: 8
Study 9638490 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not specified how many)
Number of subjects: 8
Study 9638490 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tele- and brachytherapy
Number of subjects: 8
Study 8131429 — intervention group
Group type: EXPERIMENTAL
Intervention: Videofluoroscopic evidence of aspiration (aspirating any amount of barium)
Number of subjects: 59
Study 8131429 — intervention group
Group type: EXPERIMENTAL
Intervention: Videofluoroscopic evidence of aspiration (aspirating thickened liquids or more solid consistencies)
Number of subjects: 59
Study 8131429 — intervention group
Group type: COMPARATOR
Intervention: Control group (dysphagic controls without aspiration)
Number of subjects: 59
Study 2506594 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 253
Study 2506594 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 253
Study 2506594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 236810 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg daily
Number of subjects: 45
Study 236810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31370099 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal mortality
Number of subjects: 381567
Study 31370099 — intervention group
Group type: EXPERIMENTAL
Intervention: Apgar score <7 at 5 minutes
Number of subjects: 381567
Study 31370099 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency cesarean section
Number of subjects: 381567
Study 30853361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense taxane chemotherapy (ddTC)
Number of subjects: 201
Study 30853361 — intervention group
Group type: COMPARATOR
Intervention: Conventional taxane and carboplatin chemotherapy (TC)
Number of subjects: 201
Study 30853361 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for MT subtype
Number of subjects: 201
Study 30853361 — intervention group
Group type: COMPARATOR
Intervention: Overall survival (OS) for other subtypes
Number of subjects: 201
Study 28924270 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system
Number of subjects: 76
Study 28924270 — intervention group
Group type: COMPARATOR
Intervention: Norethisterone
Number of subjects: 76
Study 25774838 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training with real-time BP feedback signals
Number of subjects: 59
Study 25774838 — intervention group
Group type: COMPARATOR
Intervention: Control group trained with pseudofeedback signals
Number of subjects: 59
Study 25774838 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (biofeedback and control)
Number of subjects: 59
Study 25059982 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 22
Study 22584132 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (n = 162)
Number of subjects: 988
Study 22584132 — intervention group
Group type: COMPARATOR
Intervention: Continuation without insulin detemir (n = 157)
Number of subjects: 988
Study 19084016 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (180 mug) weekly for 48 weeks and ribavirin (1000-1200 mg) daily for HCV genotype 1
Number of subjects: 321
Study 19084016 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a weekly for 24 weeks and ribavirin (800 mg) daily for HCV genotypes 2 or 3
Number of subjects: 321
Study 19084016 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 321
Study 16997472 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of Pain Readiness to Change (high ACT scores)
Number of subjects: 40
Study 16997472 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of Pain Readiness to Change (high ACT scores) and increased positive affect
Number of subjects: 40
Study 16997472 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Readiness to Change
Number of subjects: 40
Study 16915367 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg after pretreatment with clarithromycin 800 mg/day
Number of subjects: 21
Study 16915367 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg after pretreatment with fluvoxamine 50 mg/day
Number of subjects: 21
Study 16915367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15736352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine 0.7 mg/kg during surgery followed by PCA with cyclizine 2 mg per demand
Number of subjects: 30
Study 15736352 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.04 mg/kg during surgery followed by PCA with droperidol 0.05 mg per demand
Number of subjects: 30
Study 10598606 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg rapacuronium
Number of subjects: 0
Study 10598606 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg rapacuronium
Number of subjects: 0
Study 10598606 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (1.0 mg/kg)
Number of subjects: 0
Study 10598606 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium (0.25 mg/kg)
Number of subjects: 0
Study 10598606 — intervention group
Group type: COMPARATOR
Intervention: All groups (1.5 mg/kg rapacuronium, 2.5 mg/kg rapacuronium, succinylcholine, mivacurium)
Number of subjects: 0
Study 8595286 — intervention group
Group type: EXPERIMENTAL
Intervention: New style care (reduced schedule of visits)
Number of subjects: 2794
Study 1927129 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with Cisplatin and 5‐Fluorouracil over 6 cycles
Number of subjects: 41
Study 1927129 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with Cisplatin and 5‐Fluorouracil over 3 cycles plus Telecobalt‐irradiation to 50 Gy
Number of subjects: 41
Study 1927129 — intervention group
Group type: COMPARATOR
Intervention: Postoperative irradiation with Telecobalt to 50 Gy
Number of subjects: 41
Study 6886479 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal vaccine
Number of subjects: 249
Study 31185919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral thoracic paravertebral block combined with general anesthesia (PVB + GA)
Number of subjects: 60
Study 31185919 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 60
Study 27974316 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic obese adults
Number of subjects: 24
Study 27974316 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean healthy adults
Number of subjects: 24
Study 25539762 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (15 mg daily for 7 days)
Number of subjects: 34
Study 25539762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 24066672 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 μg Beraprost Sodium (BPS) daily for 12 weeks
Number of subjects: 102
Study 24066672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 21852698 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care at time of pregnancy confirmation with parallel partner testing (n = 191)
Number of subjects: 464
Study 21852698 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care at time of pregnancy confirmation with sequential partner testing (n = 158)
Number of subjects: 464
Study 21852698 — intervention group
Group type: COMPARATOR
Intervention: Secondary care by midwives with sequential partner testing (standard care, n = 115)
Number of subjects: 464
Study 19290709 — intervention group
Group type: EXPERIMENTAL
Intervention: Information based on social cognitive theory (SCT) targeting outcome expectations
Number of subjects: 251
Study 19290709 — intervention group
Group type: EXPERIMENTAL
Intervention: Information based on SCT + elaboration likelihood model
Number of subjects: 251
Study 19290709 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback based on self‐perception theory
Number of subjects: 251
Study 19290709 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 251
Study 17368619 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish generic reference pricing system for lovastatin
Number of subjects: 46
Study 17368619 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish generic reference pricing system for simvastatin
Number of subjects: 46
Study 17368619 — intervention group
Group type: EXPERIMENTAL
Intervention: Public interventions in Spain
Number of subjects: 46
Study 17368619 — intervention group
Group type: EXPERIMENTAL
Intervention: Public interventions in Andalusia
Number of subjects: 46
Study 14734066 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine buffered with sodium bicarbonate (pH 7.4)
Number of subjects: 64
Study 14734066 — intervention group
Group type: COMPARATOR
Intervention: Plain lidocaine (pH 6.4)
Number of subjects: 64
Study 11467693 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% clindamycin vaginal cream
Number of subjects: 168
Study 11467693 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 168
Study 9507926 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect irregular participle forms (e.g., *prendato instead of preso)
Number of subjects: 12
Study 9507926 — intervention group
Group type: COMPARATOR
Intervention: Incorrect regular participle forms (e.g., *parlito, *dormato)
Number of subjects: 12
Study 7530028 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine 10 mg i.m. 15 min before spinal anaesthesia
Number of subjects: 36
Study 7530028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no methoxamine)
Number of subjects: 36
Study 3123118 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-L-glutamyl-L-dopa (gludopa) at a dose of 25 micrograms min-1 kg-1
Number of subjects: 6
Study 3123118 — intervention group
Group type: COMPARATOR
Intervention: gamma-L-glutamyl-L-tyrosine (glutyrosine) at a dose of 25 micrograms min-1 kg-1
Number of subjects: 6
Study 31926169 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic colitis
Number of subjects: 13957
Study 30917121 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination-prevention-package (behaviour change communication, condom promotion, HIV testing, voluntary male medical circumcision, referral for anti-retroviral therapy if HIV-positive)
Number of subjects: 862
Study 30917121 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination-prevention-package
Number of subjects: 862
Study 30917121 — intervention group
Group type: COMPARATOR
Intervention: Routine government HIV care services (Control)
Number of subjects: 862
Study 30917121 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 862
Study 29141719 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus primaquine (0.25 mg base/kg/day for 14 days)
Number of subjects: 593
Study 29141719 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 593
Study 25418212 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG + BMMNC
Number of subjects: 42
Study 25418212 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 42
Study 23965321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 0
Study 23965321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21831064 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid school-based nutrition education program
Number of subjects: 12
Study 20000249 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured classroom and clinical content related to safety and quality of health care systems
Number of subjects: 0
Study 20000249 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom and clinical learning activities
Number of subjects: 0
Study 17100735 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-MOP/NB-UVB
Number of subjects: 10
Study 17100735 — intervention group
Group type: COMPARATOR
Intervention: NB-UVB
Number of subjects: 10
Study 14707788 — intervention group
Group type: EXPERIMENTAL
Intervention: GW433908 (908), 1400 mg BID
Number of subjects: 166
Study 14707788 — intervention group
Group type: COMPARATOR
Intervention: Nelfinavir (NFV), 1250 mg BID
Number of subjects: 166
Study 11595607 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 20
Study 11595607 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 20
Study 9440358 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral elbow movements with frequency ratios of 2:1 and 3:1
Number of subjects: 0
Study 9440358 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional practice in the second experiment
Number of subjects: 0